Kidney Cancer Association | Association Partnerships

March 11, 2022

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.

February 11, 2022

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

February 03, 2022

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

November 18, 2021

In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.

November 08, 2021

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

November 07, 2021

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.